TISIDB

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 3: Secreted
Domain	PF09294 Interferon-alpha/beta receptor PF01108 Tissue factor
Function	Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation (PubMed:26424569). Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1 (PubMed:8181059, PubMed:7665574, PubMed:7759950). Isoform 3 is a potent inhibitor of type I IFN receptor activity (PubMed:7759950).

> Gene Ontology [ TOP ]
Biological Process	GO:0001959 regulation of cytokine-mediated signaling pathway GO:0007259 JAK-STAT cascade GO:0009615 response to virus GO:0034340 response to type I interferon GO:0035455 response to interferon-alpha GO:0035456 response to interferon-beta GO:0045088 regulation of innate immune response GO:0051607 defense response to virus GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0071357 cellular response to type I interferon GO:0097696 STAT cascade GO:0098542 defense response to other organism
Molecular Function	GO:0004896 cytokine receptor activity GO:0004904 interferon receptor activity GO:0004905 type I interferon receptor activity GO:0019955 cytokine binding GO:0042015 interleukin-20 binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04620 Toll-like receptor signaling pathway hsa04621 NOD-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway hsa04650 Natural killer cell mediated cytotoxicity
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-912694: Regulation of IFNA signaling

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IFNAR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IFNAR2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 1.37; FDR: 0.000424	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 8.95; FDR: 0.000	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	STARS Score: 7.84; FDR: 0.000	Sensitive to T cell-mediated killing
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IFNAR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.2	0.512
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.541	0.776
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.053	0.968
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.014	0.959
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.029	0.987
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.009	0.997
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.146	0.691
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.009	0.995
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.341	0.809
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.332	0.817
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.827	0.703
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.005	0.953

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IFNAR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNAR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNAR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNAR2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNAR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IFNAR2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IFNAR2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IFNAR2
Name	interferon (alpha, beta and omega) receptor 2
Aliases	IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location	21q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IFNAR2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting IFNAR2.

ID	Name	Drug Type	Targets	#Targets
DB00008	Peginterferon alfa-2a	Biotech	IFNAR1, IFNAR2	2
DB00011	Interferon alfa-n1	Biotech	IFNAR1, IFNAR2	2
DB00018	Interferon alfa-n3	Biotech	IFNAR1, IFNAR2	2
DB00022	Peginterferon alfa-2b	Biotech	IFNAR1, IFNAR2	2
DB00034	Interferon Alfa-2a, Recombinant	Biotech	IFNAR1, IFNAR2	2
DB00060	Interferon beta-1a	Biotech	IFNAR1, IFNAR2	2
DB00068	Interferon beta-1b	Biotech	IFNAR1, IFNAR2	2
DB00069	Interferon alfacon-1	Biotech	IFNAR1, IFNAR2	2
DB00105	Interferon Alfa-2b, Recombinant	Biotech	IFNAR1, IFNAR2	2
DB05472	omega interferon	Small Molecule	IFNAR1, IFNAR2	2

Browse IFNAR2